Eli Lilly shares have recovered from a 12% pullback in late December, climbing steadily through January to approach a long-term buy point identified by technical analysts. The rebound coincides with Lilly’s announcement of a joint research initiative with Nvidia, aimed at applying artificial intelligence to accelerate early‐stage drug discovery across metabolic and neurological disease targets. Under the multi‐year agreement, Lilly will leverage Nvidia’s DGX supercomputing platform to analyze molecular simulations, with initial funding of $50 million earmarked for algorithm development and model validation.

At the 2026 JPMorgan Healthcare Conference, Lilly’s Chief Scientific Officer Dan Skovronsky outlined the company’s plan to introduce an oral GLP-1 agonist for obesity later this year, following Novo Nordisk’s recent pill approval. Skovronsky projected that oral formulations could add 5 million incremental patients by 2028 by attracting needle‐averse individuals and primary care physicians—who write roughly 70% of obesity prescriptions—to the category. He also highlighted Lilly’s patient access initiatives: a 15% cash‐price reduction on weekly injections since September and a November agreement that will bring Medicare coverage to obesity therapies in mid-2026.

Lilly expects its portfolio—comprising the Zepbound weight-loss injection, the upcoming oral GLP-1, and potential combination regimens with GIP agonists—to address diverse patient needs over the next five years. The company reported in December that over 8 million U.S. patients have initiated weekly injections since 2023, and anticipates that expanding to oral options will sustain double‐digit volume growth through 2027. In parallel, Lilly has committed $100 million to community‐based distribution programs aimed at reducing rural treatment deserts and ensuring that 90% of U.S. zip codes have an in-network provider by the end of 2026.